Digital image analysis outperforms manual biomarker assessment in breast cancer
In the spectrum of breast cancers, categorization according to the four gene expression based subtypes 'Luminal A, 'Luminal B, 'HER2 enriched, and 'Basal like' is the method of choice for prognostic and predictive value. As gene expression assays are not yet universally available, routine immunohistochemical stains act as surrogate markers for these subtypes. Thus, congruence of surrogate markers and gene expression tests is of utmost importance. In this study, 3 cohorts of primary breast cancer specimens (total n=436) with up to 28 years of survival data were scored for Ki67, ER, PR, and HER2 status manually and by digital image analysis (DIA) The results were then compared for sensitivity and specificity for the Luminal B subtype, concordance to PAM50 assays in subtype classification and prognostic power. The DIA system used was the Visiopharm Integrator System. DIA outperformed manual scoring in terms of sensitivity and specificity for the Luminal B subtype, widely considered the most challenging distinction in surrogate subclassification, and produced slightly better concordance and Cohen's k agreement with PAM50 gene expression assays. Manual biomarker scores and DIA essentially matched each other for Cox regression hazard ratios for all cause mortality. When the Nottingham combined histologic grade (Elston Ellis) was used as a prognostic surrogate, stronger Spearman's rank order correlations were produced by DIA. Prognostic value of Ki67 scores in terms of likelihood ratio kh2 (LR kh2) was higher for DIA that also added significantly more prognostic information to the manual scores (LR Dkh2) In conclusion, the system for DIA evaluated here was in most aspects a superior alternative to manual biomarker scoring. It also has the potential to reduce time consumption for pathologists, as many of the steps in the workflow are either automatic or feasible to manage without pathological expertise.
Modern Pathology